Skip to main content
RocheLaunch

Roche Gets FDA Approval for Another Label Expansion of Tecentriq

Source: Autobound Signal API · 87 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

The FDA approved Roche's Tecentriq and Tecentriq Hybreza in combination with chemotherapy for the adjuvant treatment of stage III dMMR colon cancer.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Roche RHHBY has secured yet another label expansion for its cancer immunotherapy Tecentriq (atezolizumab) in the United States. The FDA approved Tecentriq and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with fluoropyrimidine and oxaliplatin chemotherapy for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. The approval marks the 12th U.S. indication for Tecentriq and strengthens Roche's oncology portfolio by expanding its reach into an important treatment setting where the risk of cancer recurrence remains high. Year to date, shares of Roche have risen 3.5% compared with the industry 's rise of 11%. Image Source: Zacks Investment Research The FDA decision was based on the phase III ATOMIC study, which enrolled 712 patients with stage III dMMR colon cancer. The trial evaluated the addition of Tecentriq to modified (m) FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair. The study demonstrated that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% for patients receiving Tecentriq plus chemotherapy, compared with 76% for those receiving chemotherapy alone. The safety profile was consistent with...

Keep reading with a free account

The rest of this article, and every signal for Roche, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Launch

What this signalsA launch often needs new go-to-market and support spend.

Product
Tecentriq
Location
United States

More launch signals at other companies

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 9, 2026
signal_type
news
signal_subtype
launches

Use this data

Get every launch signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns launch signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/281d4dcc-e6c2-a959-9f1d-65683046eeae returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "281d4dcc-e6c2-a959-9f1d-65683046eeae",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-10-09T15:37:04+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/5397615/roche-gets-fda-approval-for-another-label-expansion-of-tecentriq/",
    "title": "Roche Gets FDA Approval for Another Label Expansion of Tecentriq - The Globe and Mail",
    "excerpt": "Roche RHHBY has secured yet another label expansion for its cancer immunotherapy Tecentriq (atezolizumab) in the United States. The FDA approved Tecentriq and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with fluoropyrimidine and oxaliplatin chemotherapy for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. The approval marks the 12th U.S. indication for Tecentriq and strengthens Roche’s oncology portfolio by expanding its reach into an important treatment setting where the risk of cancer recurrence remains high. Year to date, shares of Roche have risen 3.5% compared with the industry ’s rise of 11%. Image Source: Zacks Investment Research The FDA decision was based on the phase III ATOMIC study, which enrolled 712 patients with stage III dMMR colon cancer. The trial evaluated the addition of Tecentriq to modified (m) FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair. The study demonstrated that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% for patients receiving Tecentriq plus chemotherapy, compared with 76% for those receiving chemotherapy alone. The safety profile was consistent with...",
    "product": "Tecentriq",
    "summary": "The FDA approved Roche's Tecentriq and Tecentriq Hybreza in combination with chemotherapy for the adjuvant treatment of stage III dMMR colon cancer.",
    "location": "United States",
    "planning": false,
    "image_url": "https://www.theglobeandmail.com/pf/resources/assets/meta/twitter-summary-240x240.png?d=976",
    "confidence": 0.95,
    "product_data": {
      "name": "Tecentriq",
      "full_text": "Tecentriq and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-09T15:37:04Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The FDA approved Tecentriq and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with fluoropyrimidine and oxaliplatin chemotherapy for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.